Spots Global Cancer Trial Database for zytiga
Every month we try and update this database with for zytiga cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT02257736 | Prostatic Neopl... | Apalutamide Abiraterone ace... Prednisone Placebo | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | NCT04887506 | Metastatic Cast... Metastatic Cast... Metastatic Pros... | TAVT-45 Zytiga Prednisone | 18 Years - | Tavanta Therapeutics | |
| TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | NCT04887506 | Metastatic Cast... Metastatic Cast... Metastatic Pros... | TAVT-45 Zytiga Prednisone | 18 Years - | Tavanta Therapeutics | |
| A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | NCT02405858 | Metastatic Cast... | Abiraterone Ace... Prednisolone | 20 Years - | Janssen Pharmaceutical K.K. | |
| A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer | NCT02608359 | Prostate Cancer | Abiraterone Ace... | 18 Years - | Johnson & Johnson Private Limited | |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects | NCT06014853 | Prostate Cancer | SOL-804-F Zytiga | 19 Years - 50 Years | Bukwang Pharmaceutical | |
| A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting | NCT02364531 | Prostatic Neopl... | Abiraterone Ace... | 18 Years - | Janssen Inc. | |
| IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen | NCT01314118 | Prostate Cancer Prostatic Neopl... | abiraterone ace... | 18 Years - 99 Years | Janssen Biotech, Inc. | |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects | NCT06014853 | Prostate Cancer | SOL-804-F Zytiga | 19 Years - 50 Years | Bukwang Pharmaceutical | |
| Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | NCT01591122 | Prostate Cancer | Placebo and pre... Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer | NCT02608359 | Prostate Cancer | Abiraterone Ace... | 18 Years - | Johnson & Johnson Private Limited | |
| Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | NCT01591122 | Prostate Cancer | Placebo and pre... Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT02257736 | Prostatic Neopl... | Apalutamide Abiraterone ace... Prednisone Placebo | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study | NCT03325127 | Prostatic Neopl... | radium Ra 223 d... Zytiga Xtandi | 40 Years - | Bayer | |
| A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | NCT02405858 | Metastatic Cast... | Abiraterone Ace... Prednisolone | 20 Years - | Janssen Pharmaceutical K.K. | |
| A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | NCT01715285 | Prostate Neopla... | Abiraterone ace... Prednisone Androgen depriv... Abiraterone ace... Prednisone Plac... | 18 Years - | Janssen Research & Development, LLC | |
| Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study | NCT03325127 | Prostatic Neopl... | radium Ra 223 d... Zytiga Xtandi | 40 Years - | Bayer | |
| Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | NCT01946165 | Prostate Cancer | Abiraterone Ace... Prednisone Enzalutamide LHRHa | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
